Options
Mg. Zuñiga-San Martin, Carlos
Research Outputs
Supportive care for end-stage kidney disease: An integral part of kidney services across a range of income settings around the world
2020, Hole, Barnaby, Hemmelgarn, Brenda, Brown, Edwina, Brown, Mark, McCulloch, Mignon I., Zuñiga-San Martin, Carlos, Andreoli, Sharon P., Blake, Peter G., Couchoud, Cécile, Cueto Manzano, Alfonso M., Dreyer, Gavin, García García, Guillermo, Jager, Kitty J., McKnight, Marla, Morton, Rachael L., Murtagh, Fliss E.M., Naicker, Saraladevi, Obrador, Gregorio T., Perl, Jeffrey, Rahman, Muhibur, Shah, Kamal D., Van Biesen, Wim, Walker, Rachael C., Yeates, Karen, Zemchenkov, Alexander, Zhao, Ming-Hui, Davies, Simon J., Caskey, Fergus J.
A key component of treatment for all people with advanced kidney disease is supportive care, which aims to improve quality of life and can be provided alongside therapies intended to prolong life, such as dialysis. This article addresses the key considerations of supportive care as part of integrated end-stage kidney disease care, with particular attention paid to programs in low- and middle-income countries. Supportive care should be an integrated component of care for patients with advanced chronic kidney disease, patients receiving kidney replacement therapy (KRT), and patients receiving non-KRT conservative care. Five themes are identified: improving information on prognosis and support, developing context-specific evidence, establishing appropriate metrics for monitoring care, clearly communicating the role of supportive care, and integrating supportive care into existing health care infrastructures. This report explores some general aspects of these 5 domains, before exploring their consequences in 4 health care situations/settings: in people approaching end-stage kidney disease in high-income countries and in low- and middle-income countries, and in people discontinuing KRT in high-income countries and in low- and middle-income countries.
Challenges for sustainable end-stage kidney disease care in low-middle-income countries: The problem of the workforce
2020, Swanepoel, Charles R., McCulloch, Mignon I., Abraham, Georgi, Donner, Jo-Ann, Alrukhaimi, Mona N., Blake, Peter G., Bunnag, Sakarn, Claus, Stefaan, Dreyer, Gavin, Ghnaimat, Mohammad A., Ibhais, Fuad M., Liew, Adrian, McKnight, Marla, Yewondwossen Tadesse, Mengistu, Naicker, Saraladevi, Niang, Abdou, Obrador, Gregorio T., Perl, Jeffrey, Harun Ur, Rashid, Tonelli, Marcello, Tungsanga, Kriang, Vachharajani, Tushar, Zakharova, Elena, Zuñiga-San Martin, Carlos, Finkelstein, Fredric O.
Prevention and early detection of kidney diseases in adults and children should be a priority for any government health department. This is particularly pertinent in the low-middle-income countries, mostly in Asia, Africa, Latin America, and the Caribbean, where up to 7 million people die because of lack of end-stage kidney disease treatment. The nephrology workforce (nurses, technicians, and doctors) is limited in these countries and expanding the size and expertise of the workforce is essential to permit expansion of treatment for both chronic kidney disease and end-stage kidney disease. To achieve this will require sustained action and commitment from governments, academic medical centers, local nephrology societies, and the international nephrology community.
A small contribution to mitigate the collision of transmissible and chronic diseases, exemplified by the management of hypertension during the COVID-19 pandemic
2021, Valdés, Gloria, Zuñiga-San Martin, Carlos
We want to take up the challenge posed by Nadar and cols. in their May editorial about managing hypertension during the COVID-19 pandemic [1]. Their concern that patients with chronic illnesses would be forgotten in the fight against the paradigm of a transmissible virus and result in collateral damage reached the public domain since June [2]. In mid October the number of new confirmed cases is still increasing in the Americas, South-East Asia and Europe according to the World Health Organization [3]; lockdowns have been reinstalled in various zones and widely available vaccines are far from around the corner. In the present situation it is urgent to mitigate the collision of non-transmissible conditions with the rapid spread of the novel COVID infection by new patterns of interaction between all the protagonists involved in health care.
Increasing access to integrated ESKD care as part of universal health coverage
2019, Harris, David C.H, Davies, Simon J., Finkelstein, Fredric O., Jha, Vivekanand, Donner, Jo-Ann, Abraham, Georgi, Bello, Aminu K., Caskey, Fergus J., Garcia Garcia, Guillermo, Harden, Paul, Hemmelgarn, Brenda, Johnson, David W., Levin, Nathan W., Luyckx, Valerie A., Martin, Dominique E., McCulloch, Mignon I., Moosa, Mohammed Rafique, O’Connell, Philip J., Okpechi, Ikechi G., Pecoits Filho, Roberto, Shah, Kamal D., Sola, Laura, Swanepoel, Charles, Tonelli, Marcello, Twahir, Ahmed, van Biesen, Wim, Varghese, Cherian, Yang, Chih-Wei, Zuñiga-San Martin, Carlos
The global nephrology community recognizes the need for a cohesive strategy to address the growing problem of end-stage kidney disease (ESKD). In March 2018, the International Society of Nephrology hosted a summit on integrated ESKD care, including 92 individuals from around the globe with diverse expertise and professional backgrounds. The attendees were from 41 countries, including 16 participants from 11 low- and lower-middle–income countries. The purpose was to develop a strategic plan to improve worldwide access to integrated ESKD care, by identifying and prioritizing key activities across 8 themes: (i) estimates of ESKD burden and treatment coverage, (ii) advocacy, (iii) education and training/workforce, (iv) financing/funding models, (v) ethics, (vi) dialysis, (vii) transplantation, and (viii) conservative care. Action plans with prioritized lists of goals, activities, and key deliverables, and an overarching performance framework were developed for each theme. Examples of these key deliverables include improved data availability, integration of core registry measures and analysis to inform development of health care policy; a framework for advocacy; improved and continued stakeholder engagement; improved workforce training; equitable, efficient, and cost-effective funding models; greater understanding and greater application of ethical principles in practice and policy; definition and application of standards for safe and sustainable dialysis treatment and a set of measurable quality parameters; and integration of dialysis, transplantation, and comprehensive conservative care as ESKD treatment options within the context of overall health priorities. Intended users of the action plans include clinicians, patients and their families, scientists, industry partners, government decision makers, and advocacy organizations. Implementation of this integrated and comprehensive plan is intended to improve quality and access to care and thereby reduce serious health-related suffering of adults and children affected by ESKD worldwide.